Novavax, a vaccine development company headquartered in Gaithersburg, says its COVID-19 vaccine candidate showed 89.3% efficacy in UK clinical trials. The UK study enrolled more than 15,000 volunteers, according to a statement from Novavax on Thursday. More details will be released as data comes in, the company said. Phase 2b results in South Africa showed […]
european
January 29, 2021 |
Engage us on Facebook
Follow us on Twitter
Tweets by @mymcmedia